Five-Year Summary

Track our recent performance by year, region and major product group.

2016-17 
Constant Currency(2)
2016-17 
Reported(3)
2015-16
Reported 
2014-15 
Reported
2013-14
Reported 
2012-13
Reported
Total Operating Revenue 7,002 6,923 6,115 5,612 5,504 5,100
Sales Revenue 6,688 6,616 5,909 5,459 5,335 4,950
R&D Investment 643 645 614 463 466 427
Profit before Income Tax Expense 1,958 1,690 1,556 1,714 1,604 1,461
Net profit after tax 1,427 1,337 1,242 1,379 1,307 1,211
Net cash inflow from Operating Activities 1,247 1,179 1,364 1,361 1,312
Capital investment 861 566 414 402 450
Return on Invested Capital (%) 24.50% 26.8%(4) 31.70% 31.80% 32.60%
Basic earnings per share ($) 2.937 2.689 2.923 2.701 2.429
Dividend per share ($) 1.36 1.26 1.24 1.13 1.02
(1) For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.915264 per share (at an exchange rate of A$1.2712/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.986328 per share (at an exchange rate of NZ$1.3699/US$1.00).
(2) Constant currency removes the impact of exchange rate movements to facilitate comparability. For further details please refer to the Directors’ Report.
(3) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(4) 2016 figure includes the gain on acquisition of Novartis' global influenza business of US$176.1 million

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

Thank you for subscribing
to the CSL newsletter